Charles Zhou
Stock Analyst at UBS
(0.10)
# 4,015
Out of 4,667 analysts
9
Total ratings
25%
Success rate
-42.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FUTU Futu Holdings | Upgrades: Buy | $67 | $90.56 | -26.02% | 2 | Jan 5, 2024 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $14.54 | +10.04% | 1 | Mar 8, 2023 | |
| COGT Cogent Biosciences | Initiates: Buy | $15 | $9.17 | +63.67% | 1 | Jun 28, 2022 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $3.35 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.58 | +3,444.30% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $2.90 | +1,486.21% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $2.49 | - | 2 | Jan 22, 2020 |
Futu Holdings
Jan 5, 2024
Upgrades: Buy
Price Target: $67
Current: $90.56
Upside: -26.02%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $14.54
Upside: +10.04%
Cogent Biosciences
Jun 28, 2022
Initiates: Buy
Price Target: $15
Current: $9.17
Upside: +63.67%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $3.35
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.58
Upside: +3,444.30%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $2.90
Upside: +1,486.21%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.49
Upside: -